Japan Biosimilar Tracker · ベバシズマブ(遺伝子組換え)
Every Bevacizumab biosimilar approved in Japan against Avastin: who sells it, when it was approved, listed and launched, its price versus the originator, and uptake.
Last updated: 2026-09-28 · PMDA biosimilar list as of 2026-09
Originator: Avastin (アバスチン; 中外製薬). ← All biosimilars in Japan
| Approved | Designation | Applicant | Developer (verified) | Product (PMDA English list) |
|---|---|---|---|---|
| 2019-06-18 | bevacizumab biosimilar 1 ベバシズマブ後続1 | Pfizer Japan | – | Bevacizumab BS Intravenous Infusion 100 mg [Pfizer] Bevacizumab BS Intravenous Infusion 400 mg [Pfizer] |
| 2019-09-20 | bevacizumab biosimilar 2 ベバシズマブ後続2 | Daiichi Sankyo | – | Bevacizumab BS Intravenous Drip Infusions 100 mg “Daiichi Sankyo” Bevacizumab BS Intravenous Drip Infusions 400 mg “Daiichi Sankyo” |
| 2022-01-20 | bevacizumab biosimilar 3 ベバシズマブ後続3 | Nichi-Iko Pharmaceutical | – | Bevacizumab BS Intravenous Infusion 100 mg "Nichi-Iko" Bevacizumab BS Intravenous Infusion 400 mg "Nichi-Iko" |
| 2022-09-26 | bevacizumab biosimilar 4 ベバシズマブ後続4 | Nippon Kayaku | Celltrion [basis] | Bevacizumab BS for Intravenous Infusion 100 mg “CTNK” Bevacizumab BS for Intravenous Infusion 400 mg “CTNK” |
One row per product and strength. Price ratio = biosimilar NHI price ÷ Avastin NHI price at the identical NHI strength (“–” when no originator has the same strength).
| Product | Strength | Company | Approved | NHI listed | Launch | Price ratio | Status |
|---|---|---|---|---|---|---|---|
| ベバシズマブBS点滴静注100mg「ファイザー」 | 100mg4mL1瓶 | Pfizer Japan | 2019-06-18 | 2019-11-27 ≈ first seen on the list; between 2019-11-19 and 2019-11-27 | – | 39% | listed |
| ベバシズマブBS点滴静注400mg「ファイザー」 | 400mg16mL1瓶 | Pfizer Japan | 2019-06-18 | 2019-11-27 ≈ first seen on the list; between 2019-11-19 and 2019-11-27 | – | 39% | listed |
| ベバシズマブBS点滴静注100mg「第一三共」 | – | Daiichi Sankyo | 2019-09-20 | – | – | – | delisted or discontinued |
| ベバシズマブBS点滴静注100mg「日医工」 | 100mg4mL1瓶 | Nichi-Iko Pharmaceutical | 2022-01-20 | 2022-05-25 ≈ first seen on the list; between 2022-04-20 and 2022-05-25 | – | 41% | listed |
| ベバシズマブBS点滴静注400mg「日医工」 | 400mg16mL1瓶 | Nichi-Iko Pharmaceutical | 2022-01-20 | 2022-05-25 ≈ first seen on the list; between 2022-04-20 and 2022-05-25 | – | 39% | listed |
| ベバシズマブBS点滴静注100mg「CTNK」 | 100mg4mL1瓶 | Nippon Kayaku developer: Celltrion | 2022-09-26 | 2022-11-16 ≈ first seen on the list; between 2022-10-01 and 2022-11-16 | – | 40% | listed |
| ベバシズマブBS点滴静注400mg「CTNK」 | 400mg16mL1瓶 | Nippon Kayaku developer: Celltrion | 2022-09-26 | 2022-11-16 ≈ first seen on the list; between 2022-10-01 and 2022-11-16 | – | 40% | listed |
Product names are as on the MHLW NHI list (Japanese). Launch dates only where the company published one. Yen prices for every strength and their history: subscribers only
| Fiscal year | Biosimilar volume share | Data |
|---|---|---|
| FY2022 | 23.9% | NDB open data (FY2022) |
| FY2023 | 41.1% | NDB open data (FY2023) |
| FY2024 | 56.1% | NDB open data (FY2024) |
own calculation from MHLW NDB open data: biosimilar volume ÷ (biosimilar + reference product), converted to active ingredient, all settings combined. Not an official MHLW figure. DPC-bundled inpatient use is missing and cells under 400 are hidden (counted as 0), so small products are underestimated. Inpatient / outpatient split and value share: subscribers.
| Date | Event | Ingredient | Company | Details | Source |
|---|---|---|---|---|---|
| 2022-11-16 | NHI listing | Bevacizumab | Nippon Kayaku (developer: Celltrion) | [bevacizumab biosimilar 4] ベバシズマブBS点滴静注100mg「CTNK」, ベバシズマブBS点滴静注400mg「CTNK」 40% of originator | [source] |
| 2022-09-26 | Approval | Bevacizumab | Nippon Kayaku (developer: Celltrion) | [bevacizumab biosimilar 4] | [source] |
| 2022-05-25 | NHI listing | Bevacizumab | Nichi-Iko Pharmaceutical | [bevacizumab biosimilar 3] ベバシズマブBS点滴静注100mg「日医工」, ベバシズマブBS点滴静注400mg「日医工」 39%–41% of originator | [source] |
| 2022-01-20 | Approval | Bevacizumab | Nichi-Iko Pharmaceutical | [bevacizumab biosimilar 3] | [source] |
| 2019-11-27 | NHI listing | Bevacizumab | Pfizer Japan | [bevacizumab biosimilar 1] ベバシズマブBS点滴静注100mg「ファイザー」, ベバシズマブBS点滴静注400mg「ファイザー」 39% of originator | [source] |
| 2019-09-20 | Approval | Bevacizumab | Daiichi Sankyo | [bevacizumab biosimilar 2] | [source] |
| 2019-06-18 | Approval | Bevacizumab | Pfizer Japan | [bevacizumab biosimilar 1] | [source] |
Sources: PMDA “List of approved biosimilars” (as of 2026-09) and MHLW NHI drug price list, used under the Public Data License 1.0 — processed and translated by Japan Pharma Regulatory Brief (unofficial). Uptake figures are our own calculation from MHLW NDB open data. Company facts from each company's official release (linked). See the MHLW terms of use and PMDA's site policy. This page is not made by, affiliated with or endorsed by PMDA or MHLW. The Japanese originals prevail. Information only; not legal, medical or investment advice.
出典：独立行政法人医薬品医療機器総合機構（PMDA）『承認品目一覧（バイオ後続品）』、厚生労働省『薬価基準収載品目リスト』、『後発医薬品の有無に関する情報』、『NDBオープンデータ』、社会保障審議会医療保険部会・中央社会保険医療協議会の資料を加工して Japan Pharma Regulatory Brief が作成
Last built: · data as of 2026-09-28.